<DOC>
	<DOC>NCT03033537</DOC>
	<brief_summary>Introduction: Erectile dysfunction is a common condition with a significant effect on quality of life. Verapamil is calcium channel blocker of the phenyl alkylamine class which relaxes the tone of the smooth muscles lining blood vessels, leading to their dilatation.</brief_summary>
	<brief_title>Intracavernosal Injection of Papaverine/Verapamil Versus Papaverine/Phentolamine in Erectile Dysfunction</brief_title>
	<detailed_description>Objective: Evaluating the effect of intracavernosal injection of (Papaverine + Verapamil) and comparing it with (Papaverine + Phentolamine) in patients with erectile dysfunction. Patients and methods: Each one of the 20 erectile dysfunction patients was subjected to intracavernosal injection with (30mg Papaverine + 1mg Phentolamine), where penile duplex &amp; clinical evaluation was carried out followed by a wash out interval of 2 weeks after which each patient was subjected to the exact previous procedures using (30 mg Papaverine + 5 mg Verapamil). Keywords: Erectile dysfunction - Intracavernosal injection - Penile duplex - Phentolamine - Verapamil.</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Phentolamine</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<mesh_term>Calcium Channel Blockers</mesh_term>
	<mesh_term>Papaverine</mesh_term>
	<criteria>Married male patients suffering from erectile dysfunction and scheduled for intracavernosal injection. Responders to PDE5inhibitors; congenital or acquired penile anomalies; uncontrolled medical conditions or known hypersensitivity to verapamil; Peyronie's disease and any known bleeding or coagulation disorders.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>